Barcelona-based healthtech startup Sycai Medical, which provides AI-powered software to detect and predict cancer risk in abdominal lesions from CT and MRI scans, has secured €3 million in funding.
- Sycai Medical, founded in 2020 by Sara Toledano, Javier García, and Júlia Rodríguez-Comas, develops an assistant for detecting early-stage pre-cancerous lesions. The system defines lesions and compares images with prior scans to track their progression, aiding radiologists in their evaluations.
- The assistant analyzes CT scans for incidental findings without requiring manual input. It integrates directly into radiologists' workflows, enabling automated detection and monitoring with minimal disruption to existing processes.
Details of the deal
- The funding round was led by LUMO Labs, a Dutch venture capital firm that launched the €100 million LUMO Rise Fund to support impact-driven startups.
"From the very start of the development of the product they were present directly in hospitals and listening to doctors and patients non-stop to make sure they were building something that really helps people. I am very much looking forward to working with them on behalf of LUMO here in Barcelona," explains Jorge Blasco, Partner LUMO Labs.
- Other participants included Spanish Ship2B Ventures, Athos Capital, a Madrid-based VC focused on early-stage digital startups, and Namarel Ventures.
- The startup plans to launch its already CE-marked pancreas device across Europe, expand its certified product to include hepatic and renal lesions and validate its product in the US to obtain FDA approval.
"Successfully completing this investment round marks a significant milestone for us at a very strategic moment in the company’s evolution," co-founder and CEO, Sara Toledano, commented.
